EDEN PRAIRIE, Minn., Oct. 05, 2022 (GLOBE NEWSWIRE) — Miromatrix Medical Inc. MIRO, a life sciences company pioneering novel technology to bioengineer fully transplantable organs to save and improve patient lives, today announced that CEO Jeff Ross will step down at the 2022 Cell & Gene Meeting the Mesa will be giving a talk. The three-day event, taking place October 11-13 this year, will feature in-person and pre-recorded virtual presentations from leading public and private companies highlighting the technical and clinical advancements of the past 12 months in the fields of cell therapy, gene therapy, gene editing, and tissue engineering and regenerative medicine.
Mr. Ross will deliver his remarks at the 2022 Cell & Gene Meeting on October 12 at the Mesa in the Oxford Biomedica Ballroomth, 2022 at 6:30 p.m. ET. Registration for the conference is possible here.
About Miromatrix
Miromatrix Medical Inc. is a life sciences company pioneering novel technology for the bioengineering of fully transplantable human organs to save and improve patient lives. The Company has developed a proprietary bioengineered organ perfusion technology platform that it believes can be efficiently scaled to address the shortage of available human organs. The company’s initial development focus is on human livers and kidneys. For more information visit miromatrix.com.
investor contact
Gregory Chodaczek
347-620-7010
ir@miromatrix.com
Media contact:
press@miromatrix.com
